The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of ...

Moderna (NasdaqGS:MRNA) reported positive Phase 3 clinical data for its investigational influenza vaccine mRNA-1010 and RSV ...

CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will ...

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent ...

FDA reversal, patent relief, and mRESVIA risks show a commoditized market and lofty $20B valuation. See more here.